Support for primary care prescribing for adult ADHD in England: national survey

Anna Price; Kieran Becker; John H Ward; Obioha C Ukoumunne; Rebecca Gudka; Anita Salimi; Faraz Mughal; GJ Melendez-Torres; Jane R Smith; Tamsin Newlove-Delgado

doi:10.3399/BJGP.2023.0595

Abstract

Background Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, for which there are effective pharmacological treatments that improve symptoms and reduce complications. Guidelines published by the National Institute for Health and Care Excellence recommend that primary care practitioners prescribe medication for adult ADHD under shared-care agreements with Adult Mental Health Services (AMHS). However, provision remains uneven, with some practitioners reporting a lack of support.

Aim This study aimed to describe elements of support, and their availability/use, in primary care prescribing for adult ADHD medication in England to improve access for this underserved population and inform service improvement.

Design and setting Cross-sectional surveys were used to elicit data from commissioners, health professionals (HPs), and people with lived experience of ADHD (LE) across England about elements supporting pharmacological treatment of ADHD in primary care.

Method Three interlinked cross-sectional surveys were used to ask every integrated care board in England (commissioners), along with convenience samples of HPs and LEs, about prescribing rates, AMHS availability, wait times, and shared-care agreement protocols/policies for the pharmacological treatment of ADHD in primary care. Descriptive analyses, percentages, and confidence intervals were used to summarise responses by stakeholder group. Variations in reported provision and practice were explored and displayed visually using mapping software.

Results Data from 782 responders (42 commissioners, 331 HPs, 409 LEs) revealed differences in reported provision by stakeholder group, including for prescribing (95% of HPs versus 64% of LEs). In all, >40% of responders reported extended AMHS wait times of ≥2 years. There was some variability by NHS region – for example, London had the lowest reported extended wait time (25%), while East of England had the highest (55%).

Conclusion Elements supporting appropriate shared-care prescribing of ADHD medication via primary care are not universally available in England. Coordinated approaches are needed to address these gaps.

Introduction

Attention deficit hyperactivity disorder and prescribing

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that affects 5–7% of children and adolescents,¹^,² and 2–5% of adults.³^,⁴ It is defined by patterns of hyperactivity, impulsivity, and/or inattention that interfere with functioning in daily life, adversely impacting multiple life domains, including physical and mental health, relationships, work, and education.⁵^,⁶ Higher ADHD prevalence is associated with economic disadvantage and may lead to greater demands on services in some areas.⁷ Despite pharmacological treatments, with substantial evidence of reductions in risks of depression, suicidality, aggression, criminality, and substance-use disorders,⁸^–¹² services for ADHD appear to be insufficient in many regions of the UK. Insufficient services for ADHD are associated with high long-term social, health, personal, and economic costs.¹³ Failure to access pharmacological treatment for those who need it, can have severe impacts on families struggling to manage ADHD, with high emotional and financial costs.¹³ Understanding — and, ultimately, improving — prescribing practices has the potential to benefit the lives of patients and their communities across multiple domains.¹⁴

Improved management of attention deficit hyperactivity disorder (ADHD) in primary care has been proposed as part of the solution to the current ‘failure’ of health care for people with ADHD in England. However, GPs and other primary care professionals need better support from mental health specialists to be able to provide shared-care prescribing of ADHD medication in line with UK guidelines. This research summarises stakeholder-reported availability of the elements necessary for supported and appropriate shared-care prescribing via primary care. Any reorganisation of health care needs to ensure GPs are properly supported to prescribe for patients with ADHD, especially in areas of the country where there are high levels of unmet need.

How this fits in

Shared-care challenges

The National Institute for Health and Care Excellence (NICE) guidelines for treatment and management of ADHD state that, after titration by a mental health specialist, the prescribing and monitoring of ADHD medication should be carried out under shared-care protocol arrangements with primary care.¹⁵ Shared care, a formal local agreement between the specialist and the GP, enables GPs to share responsibility for safe prescribing and monitoring of specialist medicines. However, evidence suggests GPs may not feel supported to prescribe under shared care, with challenges including inadequate Adult Mental Health Services (AMHS) provisions and insufficient prescribing guidance.¹⁶^–¹⁸ GPs may refuse a shared-care agreement if they are not happy with the burden of responsibility and perceived risk.¹⁷^,¹⁸ Perhaps unsurprisingly, patients report multiple challenges in accessing prescriptions for ADHD medication, with access dependent on local service contexts, whether their GP facilitates shared care, and the patient’s ability to advocate for their care.¹⁹^,²⁰ Recent expert guidance recommends development of ADHD specialisms in primary care to help address these issues.²¹

Integrating care

The organisation of UK health care, including structural barriers between primary and secondary care, and children’s and adult services, can exacerbate existing health inequalities for people living with ADHD.¹³^,²²^–²⁴ Barriers include difficulties securing a referral for diagnosis, associated waitlists, challenges in transitioning to adult services, difficulties in re-accessing care after dropping out, and variability in whether GPs will prescribe.¹³^,²⁴^,²⁵ The establishment of 42 integrated care systems responsible for jointly planning and delivering health and care services in England — stipulated in the Health and Care Act 2022 — represents an opportunity to improve outcomes and tackle barriers that exacerbate healthcare inequalities for underserved groups, such as people with ADHD. Integrated care boards (ICBs) are now responsible for commissioning primary care services through approximately 1250 primary care networks, each covering populations of 30 000–50 000 patients.²⁶ Despite some primary care data evidencing the inconsistent prescribing of ADHD medication,²⁷ to date no study has focused on exploring geographic variation in prescribing practice for ADHD, or factors that support successful prescribing.

Aim

This study aimed to describe the presence of elements that support primary care prescribing of adult ADHD medication across England, incorporating the perspectives of multiple stakeholders.

Method

Design

Three linked cross-sectional electronic surveys of primary care provision for people with ADHD were developed following the seven-step method for mapping services²⁸ to capture experiences of key stakeholders — namely, commissioners, health professionals (HPs), and people with lived experience of ADHD (LEs). Surveys asked about prescribing, shared care, AMHS, and wait times (Supplementary Box S1). Content was co-designed and iteratively reviewed by the Managing young people (aged 16–25) with Attention deficit hyperactivity disorder in Primary care (MAP) study research advisory groups, to ensure stakeholder priorities were incorporated. Revisions were undertaken to reduce survey completion time (<10 minutes) and ensure accessibility. This study is linked to a wider programme of work by the same authors.²⁹

Participants

Participants comprised:

commissioners from every ICB in England, who responded in relation to the provision of NHS services in their geographic area;
HPs working in primary care (for example, GPs, practice managers, and mental health workers), who reported on provision and practice at local levels; and
LEs (for example, people with ADHD, and their supporters), who responded in relation to personal experience.

Participants had to be >16 years old and living or working in England.

Recruitment

The commissioner survey was sent via freedom of information (FOI) requests to every ICB in England in October 2022. The anonymous HP and LE surveys (open for 6 weeks from October 2022) were shared via Qualtrics (version 03.23), a secure online survey tool, using a variety of convenience sampling techniques. These included sharing links on the study’s website, via social media (Twitter [now named X] and Facebook), and with research partners (ADHD Foundation and the UK Adult ADHD Network), National Institute for Health and Care Research clinical research networks (CRNs), professional contacts, and other organisations, who distributed them via their networks. Midway through data collection, under-represented regions were identified and subsequent dissemination focused on these areas (by targeting local CRNs and ADHD support groups) with the aim of achieving adequate representation across England.

Data collection and storage were conducted in line with the UK General Data Protection Regulation.

Data analysis

Data — which comprised responses to questions on prescribing, AMHS availability, wait times, and shared care for people with ADHD from a range of reporting perspectives — were cleaned and analysed in Microsoft Excel and Stata (version 17) by two authors, and checked for accuracy by another. Responders were included in the analysis if they answered the first two survey questions, which meant they provided a postcode, and identified their role. When participants answered ‘do not know’ or missed a response, the data were treated as missing and removed for that outcome. Percentages of responders that reported availability of elements of prescribing practice were presented with 95% confidence intervals (CIs), allowing a comparison of reported provision between stakeholders and by location (ICB or NHS region).

Geographic analyses were carried out using the open-source Quantum Geographic Information System (QGIS) (version 3.26.3) and visual maps were created to display findings. Relevant location data, such as NHS region and longitude/latitude, were obtained from postcodes using a variety of look-up tools and files, such as the English Indices of Deprivation 2019 (https://imd-by-postcode.opendatacommunities.org/imd/2019), the Office for National Statistics’ Open Geography Portal (https://geoportal.statistics.gov.uk/), and the UK Grid Reference Finder (https://gridreferencefinder.com/postcodeBatchConverter/).

Results

Sample

In total, 782 responses were received — these were from commissioners (n = 42), HPs working in primary care (n = 331), and LEs (n = 409) located across England (Table 1 and Figure 1).

Figure 1.

Map showing geographic distribution of survey responders, by NHS region and stakeholder group.

View this table:

Table 1.

Participants, with sampling method, reporting perspective, and elements of prescribing in primary care on which they reported

Provision

Stakeholder responses indicated the availably of elements of support that are necessary and appropriate to support shared prescribing of adult ADHD medication in primary care, with variation by stakeholder group and NHS England (Table 2, Supplementary Table S1, and Figures 2 and 3).

View this table:

Table 2.

Reported availability of elements supporting shared-care prescribing of ADHD medication in primary care, by stakeholder group

Figure 2.

Proportions of health professionals (n = 331) reporting elements of support for primary care prescribing of adult ADHD medication by NHS region, with 95% CIs. ADHD = attention deficit and hyperactivity disorder. AMHS = Adult Mental Health Services.

Figure 3.

Proportions of patients and supporters with lived experience of ADHD (n = 409) reporting ‘elements of support’ for primary care prescribing of adult ADHD medication by NHS region, with 95% CIs. ADHD = attention deficit and hyperactivity disorder. AMHS = Adult Mental Health Services.

Commissioners

All commissioners reported available AMHS for ADHD in their ICB (Table 2), meaning this was considered available in every NHS region with no geographic variation; however, 45% confirmed extended wait times for these services of ≥2 years (Table 2). Rates of extended wait times varied by NHS region, with the lowest in the Midlands (14%) and London (24%), and the highest in the North West (100%) (see supplementary material). Although 90% of commissioners reported that at least some shared-care protocols were in place, 10% (located in the Midlands, East of England, and the South East), stated that they were not (data not shown).

HPs

Prescribing for patients (whether they had an NHS or a private diagnosis) was reported by most HPs, with 95% confirming any prescribing, and little observable difference by NHS region (Figure 2). Interestingly, HPs reported much higher prescribing rates for patients with NHS diagnoses (90%) as opposed to those with private ones (49%) (Table 2). AMHS for patients with ADHD were only reported by 79% of HPs (Table 2), with highest rates in London (100%), and the lowest in the South East (69%) (Figure 2). Extended wait times (≥2 years) were reported by 42% of HPs (Table 2), with the lowest rates in London (25%) and the highest in the East of England (55%) (Figure 2). Similarly, shared-care agreements/protocols were only reported by 79% of HPs (Table 2), with highest rates in London (100%) and the lowest in the South East (72%) (Figure 2).

LEs

Any experience of receiving prescriptions for adult ADHD medication (for example, for an NHS and/or for a private diagnosis) was reported by 64% of LEs (data not shown). When explored by reports for an NHS or private diagnosis alone, rates were similar for patients with NHS (38%) or private (40%) diagnoses (Table 2). Proportions of LE responders reporting any prescribing for adult ADHD medication were highest in London (83%), and lowest in the Midlands (56%) and South West (55%) (Figure 3). AMHS referral for ADHD was only confirmed by 56% of LE responders (Table 2), with rates highest in London (81%), and lowest in the South West (43%) and North East and Yorkshire (39%) (Figure 3). Extended wait times were reported by 37% of LEs (Table 2), with the lowest rates in the East of England (14%), and the highest in North East and Yorkshire (55%) and the South East (53%) (Figure 3).

Stakeholder variation

There was variation between stakeholder groups in several reported elements of support, with, for example, higher rates of HPs reporting prescribing of adult ADHD medication (95%), compared with LEs (64%) (data not shown). However, there was little observable difference between stakeholder reports of extended wait times for AMHS, which were reported by 45% of commissioners, 42% of HPs, and 37% of LEs respectively (Table 2). Illustrative maps are shown in Figure 4 and Supplementary Figures S1–3.

Figure 4.

Maps showing proportions of responders reporting the practice of prescribing of adult ADHD medication in primary care, by NHS region and stakeholder group (health professionals, n = 331; people with lived experience, n = 409). ADHD = attention deficit and hyperactivity disorder. AMHS = Adult Mental Health Services.

Discussion

Summary

It is perhaps reassuring that 95% of HPs reported that their practices prescribed adult ADHD medication; however, the lower proportions of LEs (64%) that reported any prescribing of ADHD medication, alongside differences between reported prescribing for patients with NHS or private diagnoses, are concerning. Although every commissioner reported having AMHS for patients with ADHD in their ICB, >40% of responders (across stakeholder groups) reported waiting lists of ≥2 years, indicating that timely support for shared-care prescribing is limited.

Strengths and limitations

This study has numerous strengths, including the use of stakeholder-informed mapping methodology, with survey design guided by stakeholder advisory groups. Use of online self-reported measures was cost-effective and enabled a wide geographic spread of responses. The 100% response rate from ICB commissioners provides an authoritative overview of provision, while the convenience samples of HPs and LEs reflects experiences of key stakeholders (such as GPs, nurses, people with ADHD, and their supporters).

The authors recognise that this study has several limitations. Online data collection may exclude responders with communication difficulties and/or without internet access. In addition, surveys can be subject to recall bias and the convenience sample is likely to have been biased towards responders with high levels of interest in ADHD and/or those experiencing challenges. Further, detailed demographic data were not collected from participants because the authors’ priority was keeping the survey short and engaging for people with ADHD; this may prevent the results from being generalisable to the wider population. Finally, the data only represent a snapshot of provision at the ≥6000 GP practices in England, and relatively low response numbers by region mean that any geographic comparison needs careful interpretation.

Comparison with existing literature

These data, presented through the lens of primary care, support, extend, and update existing research evidencing the limited availability of AMHS health services for ADHD in the UK,¹⁶^,³⁰ and lower-than-expected rates of prescribing in children, at transition, and throughout the lifespan.²⁷^,³¹^,³² Reports on the availability of AMHS from ICB commissioners implied that provision of AMHS for ADHD in England may have improved slightly, especially when compared with the fact that just over 90% of clinical commissioning groups (CCGs) reported having AMHS for ADHD in 2018.¹⁹ However, as ICBs cover a wider geographic area than CCGs, these data are not directly comparable. Variations in reported prescribing provision accord with research using routinely collected data evidencing regional variations in the prescribing of ADHD medication.²⁷

Implications for research and/or practice

This overview of stakeholder perspectives on elements of support for primary care prescribing of ADHD medication provides a useful baseline from which to track the impact of the establishment of ICBs on delivery of the NHS equity agenda.³³^,³⁴ Regional variations in most elements of support emphasise the importance of the mandated work of newly established ICBs to identify and address unmet need in their areas, especially given the higher rates of ADHD in populations with greater levels of deprivation.²³^,³⁵ Given that, in 2012, ADHD prevalence for young people was found to be double in areas of greatest deprivation compared with those with least deprivation,⁷ the ICB mandate to tackle inequalities is particularly relevant for this population.³⁴

Long wait lists mean that many AMHS are not accessible, regardless of a potential improvement in provision. Where services are limited or unavailable, it is often the patients without family support or resources to enable private health care who are most negatively impacted.⁷^,¹⁹ Addressing systems issues, such as AMHS availability and standardisation of shared care nationally, could reduce NHS variation and associated barriers to accessing primary care support for patients with ADHD.

Primary care plays a key role in prescribing and helping to ensure continuity of care for people with ADHD;¹⁹^,²⁰^,³⁶^–³⁸ however, GPs need support to feel confident to prescribe.³⁹ Even when shared-care protocols are available, GPs may be unwilling to prescribe, because of concerns around robustness of diagnosis or a perception that secondary care monitoring is inconsistent or insufficient.¹³^,¹⁸ Qualitative studies have highlighted concerns over the balance of risk and responsibilities in prescribing for ADHD, which were particularly marked where specialist services were lacking.¹⁷ It is overly simplistic to conclude that GPs need to be better trained, more aware, and more willing to prescribe. One solution to reducing the burden on GPs is providing relevant information in quick, accessible formats that can be integrated seamlessly into existing systems. Information about individual patients’ needs and care pathways should be available at the point of need, in a filtered format, placing minimal demand on GP time and energy. Future research needs to explore solutions from the perspectives of LEs and primary care HPs. Linked qualitative research suggests that digital innovations to support shared care, such as links to shared-care templates and answers to frequently asked questions, might be a cost-effective solution to help primary care providers feel more supported in prescribing for patients with ADHD.⁴⁰

Equitable healthcare provision for adults with ADHD needs to be supported by improving communications across the primary–secondary care interface and providing access to specialist colleagues.²¹^,³⁷ This could be aided by creating standardised shared-care templates, and digital information resources suitable for use by providers and patients.⁴⁰ Future research is planned to gain a better understanding of the barriers to health care for underserved groups.

Acknowledgments

The authors would like to thank all those who have contributed to this study, including the healthcare professionals, and people with ADHD and their supporters involved in the conception and planning of this research. They would also like to thank the colleagues, collaborators, and research partners who have supported every aspect of this study.

Notes

Funding

This project was funded by a National Institute for Health and Care Research (NIHR) Three Schools Mental Health Research Fellowship held by A Price (reference: MHF008) and supported by the NIHR Clinical Research Network South West Peninsula. During the preparation of this article, T Newlove-Delgado was supported by an NIHR Advanced Fellowship (reference: NIHR300056), O Ukoumunne was supported by the NIHR Applied Research Collaboration South West Peninsula, F Mughal was supported by an NIHR Doctoral Fellowship (reference: NIHR300957), and J Ward was supported by the NIHR Oxford Health Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

Ethical approval

The project was given ethical approval by the Yorkshire and the Humber — Bradford Leeds Research Ethics Committee (Reference: 22/YH/0132). Informed consent was gained from all participants in line with Health Research Authority ethics.

Data

Data are stored securely at the University of Exeter and will be made available from the lead author upon reasonable request.

Provenance

Freely submitted; externally peer reviewed.

Competing interests

The authors have declared no competing interests.

Contributors

The original research idea stemmed from development work conducted by Anna Price and Tamsin Newlove-Delgado. All authors actively contributed to the research design. Anna Price led on research project delivery, supported by Kieran Becker and Rebecca Gudka. Kieran Becker led on the geographic and statistical analyses, supported by Anna Price, Obioha Ukoumunne, and John Ward. Tamsin Newlove-Delgado and Jane Smith provided research oversight and academic mentorship. Faraz Mughal led on healthcare professional and GP representation. Anita Salimi led on patient and public involvement and engagement (PPIE) representation. GJ Melendez-Torres provided insight and oversight from a nursing and public health perspective. All authors commented on the manuscript, provided final approval for publication, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Discuss this article:

bjgp.org/letters

Received November 14, 2023.
Revision requested February 28, 2024.
Accepted April 9, 2024.

http://creativecommons.org/licenses/by/4.0/

This article is Open Access: CC BY 4.0 licence (http://creativecommons.org/licences/by/4.0/).

References

1.↵
1. Polanczyk G,
2. de Lima MS,
3. Horta BL,
4. et al.
(2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry doi:10.1176/ajp.2007.164.6.942.
OpenUrl CrossRef
2.↵
1. Willcutt EG
(2012) The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics doi:10.1007/s13311-012-0135-8.
OpenUrl CrossRef
3.↵
1. Fayyad J,
2. Sampson NA,
3. Hwang I,
4. et al.
(2017) The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys. Atten Defic Hyperact Disord doi:10.1007/s12402-016-0208-3.
OpenUrl CrossRef PubMed
4.↵
1. Song P,
2. Zha M,
3. Yang Q,
4. et al.
(2021) The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. J Glob Health doi:10.7189/jogh.11.04009.
OpenUrl CrossRef
5.↵
1. Asherson P
(2012) ADHD across the lifespan. Medicine doi:10.1016/j.mpmed.2012.08.007.
OpenUrl CrossRef
6.↵
1. Kooij JJS,
2. Bijlenga D,
3. Salerno L,
4. et al.
(2019) Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry doi:10.1016/j.eurpsy.2018.11.001.
OpenUrl CrossRef PubMed
7.↵
1. Prasad V,
2. West J,
3. Kendrick D,
4. Sayal K
(2019) Attention-deficit/hyperactivity disorder: variation by socioeconomic deprivation. Arch Dis Child doi:10.1136/archdischild-2017-314470.
OpenUrl Abstract/FREE Full Text
8.↵
1. Chen Q,
2. Sjölander A,
3. Runeson B,
4. et al.
(2014) Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ doi:10.1136/bmj.g3769.
OpenUrl CrossRef
9.
1. Chang Z,
2. D’Onofrio BM,
3. Quinn PD,
4. et al.
(2016) Medication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. Biol Psychiatry doi:10.1016/j.biopsych.2016.02.018.
OpenUrl CrossRef
10.
1. Chang Z,
2. Lichtenstein P,
3. D’Onofrio BM,
4. et al.
(2014) Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry doi:10.1001/jamapsychiatry.2013.4174.
OpenUrl CrossRef PubMed
11.
1. Chang Z,
2. Lichtenstein P,
3. Halldner L,
4. et al.
(2014) Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry doi:10.1111/jcpp.12164.
OpenUrl CrossRef
12.↵
1. Lichtenstein P,
2. Halldner L,
3. Zetterqvist J,
4. et al.
(2012) Medication for attention deficit-hyperactivity disorder and criminality. New Engl J Med doi:10.1056/NEJMoa1203241.
OpenUrl CrossRef PubMed
13.↵
1. Young S,
2. Asherson P,
3. Lloyd T,
4. et al.
(2021) Failure of healthcare provision for attention-deficit/hyperactivity disorder in the United Kingdom: a consensus statement. Front Psychiatry doi:10.3389/fpsyt.2021.649399.
OpenUrl CrossRef PubMed
14.↵
1. Cubbin S,
2. Leaver L,
3. Parry A
(2020) Attention deficit hyperactivity disorder in adults: common in primary care, misdiagnosed, and impairing, but highly responsive to treatment. Br J Gen Pract, https://doi.org/10.3399/bjgp20X712553.
15.↵
1. National Institute for Health and Care Excellence
(2019) Attention deficit hyperactivity disorder: diagnosis and management NG87 (NICE, London) https://www.nice.org.uk/guidance/ng87 (accessed 19 Aug 2024).
16.↵
1. Price A,
2. Janssens A,
3. Newlove-Delgado T,
4. et al.
(2020) Mapping UK mental health services for adults with attention-deficit/hyperactivity disorder: national survey with comparison of reporting between three stakeholder groups. BJPsych Open doi:10.1192/bjo.2020.65.
OpenUrl CrossRef
17.↵
1. Newlove-Delgado T,
2. Blake S,
3. Ford T,
4. Janssens A
(2019) Young people with attention deficit hyperactivity disorder in transition from child to adult services: a qualitative study of the experiences of general practitioners in the UK. BMC Fam Pract doi:10.1186/s12875-019-1046-0.
OpenUrl CrossRef
18.↵
1. Carrington IM,
2. McAloon J
(2018) Why shared-care arrangements for prescribing in attention deficit hyperactivity disorder may not be accepted. Eur J Hosp Pharm doi:10.1136/ejhpharm-2015-000743.
OpenUrl CrossRef
19.↵
1. Janssens A,
2. Eke H,
3. Price A,
4. et al.
(2020) The transition from children’s services to adult services for young people with attention deficit hyperactivity disorder: the CATCh-uS mixed-methods study. Health Serv Deliv Res doi:10.3310/hsdr08420.
OpenUrl CrossRef
20.↵
1. Price A,
2. Newlove-Delgado T,
3. Eke H,
4. et al.
(2019) In transition with ADHD: the role of information, in facilitating or impeding young people’s transition into adult services. BMC Psychiatry doi:10.1186/s12888-019-2284-3.
OpenUrl CrossRef
21.↵
1. Asherson P,
2. Leaver L,
3. Adamou M,
4. et al.
(2022) Mainstreaming adult ADHD into primary care in the UK: guidance, practice, and best practice recommendations. BMC Psychiatry doi:10.1186/s12888-022-04290-7.
OpenUrl CrossRef PubMed
22.↵
1. Russell AE,
2. Ford T,
3. Russell G
(2015) Socioeconomic associations with ADHD: findings from a mediation analysis. PLoS One doi:10.1371/journal.pone.0128248.
OpenUrl CrossRef
23.↵
1. Russell AE,
2. Ford T,
3. Russell G
(2018) The relationship between financial difficulty and childhood symptoms of attention deficit/hyperactivity disorder: a UK longitudinal cohort study. Soc Psychiatry Psychiatr Epidemiol doi:10.1007/s00127-017-1453-2.
24.↵
1. Price A,
2. Janssens A,
3. Woodley AL,
4. et al.
(2019) Review: experiences of healthcare transitions for young people with attention deficit hyperactivity disorder: a systematic review of qualitative research. Child Adolesc Ment Health doi:10.1111/camh.12297.
OpenUrl CrossRef
25.↵
1. Young S,
2. Adamou M,
3. Asherson P,
4. et al.
(2016) Recommendations for the transition of patients with ADHD from child to adult healthcare services: a consensus statement from the UK adult ADHD network. BMC Psychiatry doi:10.1186/s12888-016-1013-4.
OpenUrl CrossRef
26.↵
1. Morciano M,
2. Checkland K,
3. Hammond J,
4. et al.
(2020) Variability in size and characteristics of primary care networks in England: observational study. Br J Gen Pract, https://doi.org/10.3399/bjgp20X713441.
27.↵
1. Price A,
2. Ford T,
3. Janssens A,
4. et al.
(2020) Regional analysis of UK primary care prescribing and adult service referrals for young people with attention-deficit hyperactivity disorder. BJPsych Open doi:10.1192/bjo.2019.94.
OpenUrl CrossRef
28.↵
1. Price A,
2. Janssens A,
3. Dunn-Morua S,
4. et al.
(2019) Seven steps to mapping health service provision: lessons learned from mapping services for adults with attention-deficit/hyperactivity disorder (ADHD) in the UK. BMC Health Serv Res doi:10.1186/s12913-019-4287-7.
OpenUrl CrossRef
29.↵
1. Price A,
2. Smith J,
3. Mughal F,
4. et al.
(2023) Protocol for the mixed methods, Managing young people (aged 16–25) with Attention deficit hyperactivity disorder in Primary care (MAP) study: mapping current practice and co-producing guidance to improve healthcare in an underserved population. BMJ Open doi:10.1136/bmjopen-2022-068184.
OpenUrl Abstract/FREE Full Text
30.↵
1. Tettenborn M,
2. Prasad S,
3. Poole L,
4. et al.
(2008) The provision and nature of ADHD services for children/adolescents in the UK: results from a nationwide survey. Clin Child Psychol Psychiatry doi:10.1177/1359104507086347.
OpenUrl CrossRef PubMed
31.↵
1. Newlove-Delgado T,
2. Hamilton W,
3. Ford TJ,
4. et al.
(2019) Prescribing for young people with attention deficit hyperactivity disorder in UK primary care: analysis of data from the Clinical Practice Research Datalink. Atten Defic Hyperact Disord doi:10.1007/s12402-019-00288-6.
OpenUrl CrossRef
32.↵
1. McCarthy S,
2. Wilton L,
3. Murray ML,
4. et al.
(2012) The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr doi:10.1186/1471-2431-12-78.
OpenUrl CrossRef PubMed
33.↵
1. NHS
(2019) The NHS long term plan. https://www.longtermplan.nhs.uk/publication/nhs-long-term-plan/(accessed 22 Apr 2024).
34.↵
1. NHS England
Integrated care boards in England. https://www.england.nhs.uk/publication/integrated-care-boards-in-england/ (accessed 22 Apr 2024).
35.↵
1. Hire AJ,
2. Ashcroft DM,
3. Springate DA,
4. Steinke DT
(2018) ADHD in the United Kingdom: regional and socioeconomic variations in incidence rates amongst children and adolescents (2004–2013). J Atten Disord doi:10.1177/1087054715613441.
36.↵
1. French B,
2. Sayal K,
3. Daley D
(2019) Barriers and facilitators to understanding of ADHD in primary care: a mixed-method systematic review. Eur Child Adolesc Psychiatry doi:10.1007/s00787-018-1256-3.
OpenUrl CrossRef
37.↵
1. Coghill DR
(2017) Organisation of services for managing ADHD. Epidemiol Psychiatr Sci doi:10.1017/S2045796016000937.
OpenUrl CrossRef
38.↵
1. Appleton R,
2. Lowe J,
3. Mughal F
(2022) Young people who have fallen through the mental health transition gap: a qualitative study on primary care support. Br J Gen Pract, https://doi.org/10.3399/BJGP.2021.0678.
39.↵
1. Rashid A,
2. Llanwarne N,
3. Lehman R
(2018) Prescribing for ADHD in primary care. Br J Gen Pract, https://doi.org/10.3399/bjgp18X695357.
40.↵
1. Gudka R,
2. Becker K,
3. Ward J,
4. et al.
(2024) Primary care provision for young people with ADHD: a multi-perspective qualitative study. Br J Gen Pract, https://doi.org/10.3399/BJGP.2023.0626.

Online First

Download PDF

Download PowerPoint

Email Article

Citation Tools

Keywords

More in this TOC Section

Show more Research

Cited By...

Intended for Healthcare Professionals

Tweets by @BJGPjournal

[1] 1.↵
Polanczyk G,
de Lima MS,
Horta BL,
et al.
(2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry doi:10.1176/ajp.2007.164.6.942.
OpenUrl CrossRef

[2] Polanczyk G,

[3] de Lima MS,

[4] Horta BL,

[5] et al.

[6] 2.↵
Willcutt EG
(2012) The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics doi:10.1007/s13311-012-0135-8.
OpenUrl CrossRef

[7] Willcutt EG

[8] 3.↵
Fayyad J,
Sampson NA,
Hwang I,
et al.
(2017) The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys. Atten Defic Hyperact Disord doi:10.1007/s12402-016-0208-3.
OpenUrl CrossRef PubMed

[9] Fayyad J,

[10] Sampson NA,

[11] Hwang I,

[12] et al.

[13] 4.↵
Song P,
Zha M,
Yang Q,
et al.
(2021) The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. J Glob Health doi:10.7189/jogh.11.04009.
OpenUrl CrossRef

[14] Song P,

[15] Zha M,

[16] Yang Q,

[17] et al.

[18] 5.↵
Asherson P
(2012) ADHD across the lifespan. Medicine doi:10.1016/j.mpmed.2012.08.007.
OpenUrl CrossRef

[19] Asherson P

[20] 6.↵
Kooij JJS,
Bijlenga D,
Salerno L,
et al.
(2019) Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry doi:10.1016/j.eurpsy.2018.11.001.
OpenUrl CrossRef PubMed

[21] Kooij JJS,

[22] Bijlenga D,

[23] Salerno L,

[24] et al.

[25] 7.↵
Prasad V,
West J,
Kendrick D,
Sayal K
(2019) Attention-deficit/hyperactivity disorder: variation by socioeconomic deprivation. Arch Dis Child doi:10.1136/archdischild-2017-314470.
OpenUrl Abstract/FREE Full Text

[26] Prasad V,

[27] West J,

[28] Kendrick D,

[29] Sayal K

[30] 8.↵
Chen Q,
Sjölander A,
Runeson B,
et al.
(2014) Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ doi:10.1136/bmj.g3769.
OpenUrl CrossRef

[31] Chen Q,

[32] Sjölander A,

[33] Runeson B,

[34] et al.

[35] 9.
Chang Z,
D’Onofrio BM,
Quinn PD,
et al.
(2016) Medication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. Biol Psychiatry doi:10.1016/j.biopsych.2016.02.018.
OpenUrl CrossRef

[36] Chang Z,

[37] D’Onofrio BM,

[38] Quinn PD,

[39] et al.

[40] 10.
Chang Z,
Lichtenstein P,
D’Onofrio BM,
et al.
(2014) Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry doi:10.1001/jamapsychiatry.2013.4174.
OpenUrl CrossRef PubMed

[41] Chang Z,

[42] Lichtenstein P,

[43] D’Onofrio BM,

[44] et al.

[45] 11.
Chang Z,
Lichtenstein P,
Halldner L,
et al.
(2014) Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry doi:10.1111/jcpp.12164.
OpenUrl CrossRef

[46] Chang Z,

[47] Lichtenstein P,

[48] Halldner L,

[49] et al.

[50] 12.↵
Lichtenstein P,
Halldner L,
Zetterqvist J,
et al.
(2012) Medication for attention deficit-hyperactivity disorder and criminality. New Engl J Med doi:10.1056/NEJMoa1203241.
OpenUrl CrossRef PubMed

[51] Lichtenstein P,

[52] Halldner L,

[53] Zetterqvist J,

[54] et al.

[55] 13.↵
Young S,
Asherson P,
Lloyd T,
et al.
(2021) Failure of healthcare provision for attention-deficit/hyperactivity disorder in the United Kingdom: a consensus statement. Front Psychiatry doi:10.3389/fpsyt.2021.649399.
OpenUrl CrossRef PubMed

[56] Young S,

[57] Asherson P,

[58] Lloyd T,

[59] et al.

[60] 14.↵
Cubbin S,
Leaver L,
Parry A
(2020) Attention deficit hyperactivity disorder in adults: common in primary care, misdiagnosed, and impairing, but highly responsive to treatment. Br J Gen Pract, https://doi.org/10.3399/bjgp20X712553.

[61] Cubbin S,

[62] Leaver L,

[63] Parry A

[64] 15.↵
National Institute for Health and Care Excellence
(2019) Attention deficit hyperactivity disorder: diagnosis and management NG87 (NICE, London) https://www.nice.org.uk/guidance/ng87 (accessed 19 Aug 2024).

[65] National Institute for Health and Care Excellence

[66] 16.↵
Price A,
Janssens A,
Newlove-Delgado T,
et al.
(2020) Mapping UK mental health services for adults with attention-deficit/hyperactivity disorder: national survey with comparison of reporting between three stakeholder groups. BJPsych Open doi:10.1192/bjo.2020.65.
OpenUrl CrossRef

[67] Price A,

[68] Janssens A,

[69] Newlove-Delgado T,

[70] et al.

[71] 17.↵
Newlove-Delgado T,
Blake S,
Ford T,
Janssens A
(2019) Young people with attention deficit hyperactivity disorder in transition from child to adult services: a qualitative study of the experiences of general practitioners in the UK. BMC Fam Pract doi:10.1186/s12875-019-1046-0.
OpenUrl CrossRef

[72] Newlove-Delgado T,

[73] Blake S,

[74] Ford T,

[75] Janssens A

[76] 18.↵
Carrington IM,
McAloon J
(2018) Why shared-care arrangements for prescribing in attention deficit hyperactivity disorder may not be accepted. Eur J Hosp Pharm doi:10.1136/ejhpharm-2015-000743.
OpenUrl CrossRef

[77] Carrington IM,

[78] McAloon J

[79] 19.↵
Janssens A,
Eke H,
Price A,
et al.
(2020) The transition from children’s services to adult services for young people with attention deficit hyperactivity disorder: the CATCh-uS mixed-methods study. Health Serv Deliv Res doi:10.3310/hsdr08420.
OpenUrl CrossRef

[80] Janssens A,

[81] Eke H,

[82] Price A,

[83] et al.

[84] 20.↵
Price A,
Newlove-Delgado T,
Eke H,
et al.
(2019) In transition with ADHD: the role of information, in facilitating or impeding young people’s transition into adult services. BMC Psychiatry doi:10.1186/s12888-019-2284-3.
OpenUrl CrossRef

[85] Price A,

[86] Newlove-Delgado T,

[87] Eke H,

[88] et al.

[89] 21.↵
Asherson P,
Leaver L,
Adamou M,
et al.
(2022) Mainstreaming adult ADHD into primary care in the UK: guidance, practice, and best practice recommendations. BMC Psychiatry doi:10.1186/s12888-022-04290-7.
OpenUrl CrossRef PubMed

[90] Asherson P,

[91] Leaver L,

[92] Adamou M,

[93] et al.

[94] 22.↵
Russell AE,
Ford T,
Russell G
(2015) Socioeconomic associations with ADHD: findings from a mediation analysis. PLoS One doi:10.1371/journal.pone.0128248.
OpenUrl CrossRef

[95] Russell AE,

[96] Ford T,

[97] Russell G

[98] 23.↵
Russell AE,
Ford T,
Russell G
(2018) The relationship between financial difficulty and childhood symptoms of attention deficit/hyperactivity disorder: a UK longitudinal cohort study. Soc Psychiatry Psychiatr Epidemiol doi:10.1007/s00127-017-1453-2.

[99] Russell AE,

[100] Ford T,

[101] Russell G

[102] 24.↵
Price A,
Janssens A,
Woodley AL,
et al.
(2019) Review: experiences of healthcare transitions for young people with attention deficit hyperactivity disorder: a systematic review of qualitative research. Child Adolesc Ment Health doi:10.1111/camh.12297.
OpenUrl CrossRef

[103] Price A,

[104] Janssens A,

[105] Woodley AL,

[106] et al.

[107] 25.↵
Young S,
Adamou M,
Asherson P,
et al.
(2016) Recommendations for the transition of patients with ADHD from child to adult healthcare services: a consensus statement from the UK adult ADHD network. BMC Psychiatry doi:10.1186/s12888-016-1013-4.
OpenUrl CrossRef

[108] Young S,

[109] Adamou M,

[110] Asherson P,

[111] et al.

[112] 26.↵
Morciano M,
Checkland K,
Hammond J,
et al.
(2020) Variability in size and characteristics of primary care networks in England: observational study. Br J Gen Pract, https://doi.org/10.3399/bjgp20X713441.

[113] Morciano M,

[114] Checkland K,

[115] Hammond J,

[116] et al.

[117] 27.↵
Price A,
Ford T,
Janssens A,
et al.
(2020) Regional analysis of UK primary care prescribing and adult service referrals for young people with attention-deficit hyperactivity disorder. BJPsych Open doi:10.1192/bjo.2019.94.
OpenUrl CrossRef

[118] Price A,

[119] Ford T,

[120] Janssens A,

[121] et al.

[122] 28.↵
Price A,
Janssens A,
Dunn-Morua S,
et al.
(2019) Seven steps to mapping health service provision: lessons learned from mapping services for adults with attention-deficit/hyperactivity disorder (ADHD) in the UK. BMC Health Serv Res doi:10.1186/s12913-019-4287-7.
OpenUrl CrossRef

[123] Price A,

[124] Janssens A,

[125] Dunn-Morua S,

[126] et al.

[127] 29.↵
Price A,
Smith J,
Mughal F,
et al.
(2023) Protocol for the mixed methods, Managing young people (aged 16–25) with Attention deficit hyperactivity disorder in Primary care (MAP) study: mapping current practice and co-producing guidance to improve healthcare in an underserved population. BMJ Open doi:10.1136/bmjopen-2022-068184.
OpenUrl Abstract/FREE Full Text

[128] Price A,

[129] Smith J,

[130] Mughal F,

[131] et al.

[132] 30.↵
Tettenborn M,
Prasad S,
Poole L,
et al.
(2008) The provision and nature of ADHD services for children/adolescents in the UK: results from a nationwide survey. Clin Child Psychol Psychiatry doi:10.1177/1359104507086347.
OpenUrl CrossRef PubMed

[133] Tettenborn M,

[134] Prasad S,

[135] Poole L,

[136] et al.

[137] 31.↵
Newlove-Delgado T,
Hamilton W,
Ford TJ,
et al.
(2019) Prescribing for young people with attention deficit hyperactivity disorder in UK primary care: analysis of data from the Clinical Practice Research Datalink. Atten Defic Hyperact Disord doi:10.1007/s12402-019-00288-6.
OpenUrl CrossRef

[138] Newlove-Delgado T,

[139] Hamilton W,

[140] Ford TJ,

[141] et al.

[142] 32.↵
McCarthy S,
Wilton L,
Murray ML,
et al.
(2012) The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr doi:10.1186/1471-2431-12-78.
OpenUrl CrossRef PubMed

[143] McCarthy S,

[144] Wilton L,

[145] Murray ML,

[146] et al.

[147] 33.↵
NHS
(2019) The NHS long term plan. https://www.longtermplan.nhs.uk/publication/nhs-long-term-plan/(accessed 22 Apr 2024).

[148] NHS

[149] 34.↵
NHS England
Integrated care boards in England. https://www.england.nhs.uk/publication/integrated-care-boards-in-england/ (accessed 22 Apr 2024).

[150] NHS England

[151] 35.↵
Hire AJ,
Ashcroft DM,
Springate DA,
Steinke DT
(2018) ADHD in the United Kingdom: regional and socioeconomic variations in incidence rates amongst children and adolescents (2004–2013). J Atten Disord doi:10.1177/1087054715613441.

[152] Hire AJ,

[153] Ashcroft DM,

[154] Springate DA,

[155] Steinke DT

[156] 36.↵
French B,
Sayal K,
Daley D
(2019) Barriers and facilitators to understanding of ADHD in primary care: a mixed-method systematic review. Eur Child Adolesc Psychiatry doi:10.1007/s00787-018-1256-3.
OpenUrl CrossRef

[157] French B,

[158] Sayal K,

[159] Daley D

[160] 37.↵
Coghill DR
(2017) Organisation of services for managing ADHD. Epidemiol Psychiatr Sci doi:10.1017/S2045796016000937.
OpenUrl CrossRef

[161] Coghill DR

[162] 38.↵
Appleton R,
Lowe J,
Mughal F
(2022) Young people who have fallen through the mental health transition gap: a qualitative study on primary care support. Br J Gen Pract, https://doi.org/10.3399/BJGP.2021.0678.

[163] Appleton R,

[164] Lowe J,

[165] Mughal F

[166] 39.↵
Rashid A,
Llanwarne N,
Lehman R
(2018) Prescribing for ADHD in primary care. Br J Gen Pract, https://doi.org/10.3399/bjgp18X695357.

[167] Rashid A,

[168] Llanwarne N,

[169] Lehman R

[170] 40.↵
Gudka R,
Becker K,
Ward J,
et al.
(2024) Primary care provision for young people with ADHD: a multi-perspective qualitative study. Br J Gen Pract, https://doi.org/10.3399/BJGP.2023.0626.

[171] Gudka R,

[172] Becker K,

[173] Ward J,

[174] et al.

Main menu

User menu

Search

Support for primary care prescribing for adult ADHD in England: national survey

Abstract

Introduction

Attention deficit hyperactivity disorder and prescribing

Shared-care challenges

Integrating care

Aim

Method

Design

Participants

Recruitment

Data analysis

Results

Sample

Provision

Commissioners

HPs

LEs

Stakeholder variation

Discussion

Summary

Strengths and limitations

Comparison with existing literature

Implications for research and/or practice

Acknowledgments

Notes

Funding

Ethical approval

Data

Provenance

Competing interests

Contributors

Discuss this article:

References

Citation Manager Formats

Jump to section

Keywords

More in this TOC Section

Related Articles

Cited By...

NAVIGATE

RCGP

MY ACCOUNT

NEWS AND UPDATES

AUTHORS & REVIEWERS

CUSTOMER SERVICES

CONTRIBUTE

CONTACT US